IL17A and Hyperglycemia: Furthermore, administration of an IL-17 blocker reduces the pathogenicity of the oral microbiota in diabetic mice [40], and STZ-treated IL-17–knockout mice show decreased hyperglycemia and insulitis compared to control mice [41].